{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "0ab7dc2b",
   "metadata": {},
   "source": [
    "# 3.Text mining"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "35dda035",
   "metadata": {},
   "source": [
    "Since biopython only work for python2 in my computer, before doing the following task, **please change the Kernel from python3 to python2.**<br>\n",
    "1.Using Biopython, collect medline abstracts on \"medulloblastoma\" published in 2012. Save the data to disk as a CSV table."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "id": "d20cf938",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Name: biopython\n",
      "Version: 1.76\n",
      "Summary: Freely available tools for computational molecular biology.\n",
      "Home-page: https://biopython.org/\n",
      "Author: The Biopython Contributors\n",
      "Author-email: biopython@biopython.org\n",
      "License: UNKNOWN\n",
      "Location: d:\\users\\punyung\\anaconda3\\envs\\scripts\\lib\\site-packages\n",
      "Requires: numpy\n",
      "Required-by: \n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "DEPRECATION: Python 2.7 will reach the end of its life on January 1st, 2020. Please upgrade your Python as Python 2.7 won't be maintained after that date. A future version of pip will drop support for Python 2.7. More details about Python 2 support in pip, can be found at https://pip.pypa.io/en/latest/development/release-process/#python-2-support\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Package         Version            \n",
      "--------------- -------------------\n",
      "biopython       1.76               \n",
      "certifi         2019.11.28         \n",
      "chardet         4.0.0              \n",
      "idna            2.10               \n",
      "numpy           1.16.6             \n",
      "panda           0.3.1              \n",
      "pandas          0.24.2             \n",
      "pip             19.3.1             \n",
      "python-dateutil 2.8.2              \n",
      "pytz            2023.3             \n",
      "requests        2.27.1             \n",
      "setuptools      44.0.0.post20200106\n",
      "six             1.16.0             \n",
      "urllib3         1.26.16            \n",
      "wheel           0.37.1             \n",
      "wincertstore    0.2                \n",
      "D:\\Users\\punyung\\anaconda3\\python.exe\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "DEPRECATION: Python 2.7 will reach the end of its life on January 1st, 2020. Please upgrade your Python as Python 2.7 won't be maintained after that date. A future version of pip will drop support for Python 2.7. More details about Python 2 support in pip, can be found at https://pip.pypa.io/en/latest/development/release-process/#python-2-support\n"
     ]
    }
   ],
   "source": [
    "# install biopython \n",
    "!pip show biopython\n",
    "#!pip uninstall biopython\n",
    "!pip list\n",
    "import sys\n",
    "print(sys.executable)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "id": "ca562d8e",
   "metadata": {
    "scrolled": true
   },
   "outputs": [],
   "source": [
    "from Bio import Entrez\n",
    "import csv\n",
    "# Set the email address to be used for accessing the Entrez database\n",
    "Entrez.email = 'punyung@163.com'\n",
    "# Search for Medline abstracts on \"medulloblastoma\" published in 2012\n",
    "search_term = 'medulloblastoma'\n",
    "search_results = Entrez.read(Entrez.esearch(db='pubmed', term=search_term, datetype='pdat', mindate='2012/01/01', maxdate='2012/12/31'))\n",
    "\n",
    "# Fetch the abstracts using the unique IDs obtained from the search results\n",
    "id_list = search_results['IdList']\n",
    "fetch_handle = Entrez.efetch(db='pubmed', id=id_list, rettype='abstract', retmode='text')\n",
    "fetch_data = fetch_handle.read()\n",
    "fetch_handle.close()\n",
    "\n",
    "# Save the fetched data as a CSV table\n",
    "csv_filename = 'medulloblastoma_abstracts_2012.csv'\n",
    "#with open(csv_filename, 'w', encoding='utf-8') as csvfile:\n",
    "with open(csv_filename, 'w') as csvfile:\n",
    "    csv_writer = csv.writer(csvfile)\n",
    "    csv_writer.writerow(['Abstract'])\n",
    "    for abstract in fetch_data.split('\\n\\n'):\n",
    "        csv_writer.writerow([abstract])"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "79628f2f",
   "metadata": {},
   "source": [
    "2.Import the CSV table and build a SQLite database."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "23506121",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "database open successfully!\n"
     ]
    }
   ],
   "source": [
    "# Import the CSV data into a SQLite database\n",
    "import sqlite3\n",
    "from Bio import Entrez\n",
    "import csv\n",
    "\n",
    "db_filename = 'medulloblastoma_abstracts.db'\n",
    "conn = sqlite3.connect(db_filename,timeout=10)\n",
    "cursor = conn.cursor()\n",
    "print (\"database open successfully!\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "310b44a7",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<sqlite3.Cursor at 0x48b7f10>"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Create a table in the database to store the abstracts\n",
    "cursor.execute('CREATE TABLE IF NOT EXISTS abstracts (id INTEGER PRIMARY KEY AUTOINCREMENT, abstract TEXT)')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "c3e249d4",
   "metadata": {},
   "outputs": [],
   "source": [
    "csv_filename = 'medulloblastoma_abstracts_2012.csv'\n",
    "with open(csv_filename, 'r') as csvfile:\n",
    "    csv_data = [row.decode('utf-8') for row in csvfile]\n",
    "    \n",
    "# Insert the CSV data into the database\n",
    "for data_row in csv_data:\n",
    "    cursor.execute('INSERT INTO abstracts (abstract)VALUES (?)', (data_row,))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "67d4329f",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "ID =  Abstract\r\n",
      "\n",
      "ID =  1. Small-molecule antagonists of Gli function.\r\n",
      "\n",
      "ID =  \"Ardecky R(1), Magnuson GK(1), Zou J(1), Ganji SR(1), Brown B(1), Ngo T(1), Lee \n",
      "\n",
      "ID =  J(1), Zeng FY(1), Sun Q(1), Stonich D(1), Salaniwal S(1), Sakata T(2), Rack \n",
      "\n",
      "ID =  PG(2), Casabar JKT(2), Mangravita-Novo A(3), Smith LH(3), Sergienko E(1), Chung \n",
      "\n",
      "ID =  TDY(1), Pinkerton AB(1), Pass I(1), Chen JK(2).\"\r\n",
      "\n",
      "ID =  \"In: Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda \n",
      "\n",
      "ID =  (MD): National Center for Biotechnology Information (US); 2010–.\n",
      "\n",
      "ID =  2012 Dec 17 [updated 2014 May 13].\"\r\n",
      "\n",
      "ID =  \"Author information:\n",
      "\n",
      "ID =  (1)Sanford-Burnham Center for Chemical Genomics at Sanford-Burnham Medical \n",
      "\n",
      "ID =  Research Institute, La Jolla, California 92037, USA\n",
      "\n",
      "ID =  (2)Department of Chemical and Systems Biology, Stanford University, Stanford, \n",
      "\n",
      "ID =  California 94305, USA.\n",
      "\n",
      "ID =  (3)Sanford-Burnham Center for Chemical Genomics at Sanford-Burnham Medical \n",
      "\n",
      "ID =  Research Institute, Orlando, Florida 32827, USA.\"\r\n",
      "\n",
      "ID =  \"As cancer treatments have shifted toward targeted therapies, the role of \n",
      "\n",
      "ID =  developmental signaling pathways in tumorigenesis has garnered special \n",
      "\n",
      "ID =  attention. For example, the Hedgehog (Hh) pathway is required for cerebellar \n",
      "\n",
      "ID =  development, and its constitutive activation can lead to pediatric \n",
      "\n",
      "ID =  medulloblastomas. Hh signaling is normally initiated by the binding of Hh \n",
      "\n",
      "ID =  ligands (Shh, Ihh, and Dhh) to the 12TM Patched1 (Ptch1) receptor resulting in \n",
      "\n",
      "ID =  accumulation and activation of the G protein-coupled receptor-like protein \n",
      "\n",
      "ID =  Smoothened (Smo) within the primary cilium. How Smo regulates Gli transcription \n",
      "\n",
      "ID =  factor function remains unclear, but this process involve the scaffolding \n",
      "\n",
      "ID =  protein Suppressor of Fused (Sufu), which can directly inhibit the Gli proteins \n",
      "\n",
      "ID =  and facilitate their proteolytic processing into N-terminal repressors. Smo is \n",
      "\n",
      "ID =  perhaps the most “druggable” target within the Hh pathway, and Smo inhibitors \n",
      "\n",
      "ID =  have demonstrated efficacy in murine tumor models and human clinical trials. \n",
      "\n",
      "ID =  However, certain cancers can proliferate in response to Gli activation through \n",
      "\n",
      "ID =  noncanonical mechanisms and therefore are insensitive to Smo inhibitors. Tumors \n",
      "\n",
      "ID =  that initially respond to Smo antagonists can also acquire mutations in Smo or \n",
      "\n",
      "ID =  downstream pathway components that render them resistant to these \n",
      "\n",
      "ID =  chemotherapies. Chemical inhibitors that act downstream of Smo therefore \n",
      "\n",
      "ID =  constitute an important therapeutic strategy for the treatment of Hh \n",
      "\n",
      "ID =  pathway-dependent cancers. Most current approaches are biased overwhelmingly to \n",
      "\n",
      "ID =  find Smo antagonists or use non-physiological overexpressed Gli cell systems. We \n",
      "\n",
      "ID =  overcame these limitations by employing a cell-based reporter that lacks Sufu \n",
      "\n",
      "ID =  (Sufu-KO-LIGHT cells) and exhibits constitutive Hh target gene expression in \n",
      "\n",
      "ID =  response to endogenous Gli activators to interrogate the MLSMR. We report here \n",
      "\n",
      "ID =  for the first time on a novel potent (33.6 nM IC50), non-cytotoxic small \n",
      "\n",
      "ID =  molecule antagonist of Gli function that does not inhibit Wnt3a signaling.\"\r\n",
      "\n",
      "ID =  PMID: 24049850\r\n",
      "\n",
      "ID =  \"\n",
      "\n",
      "ID =  2. Cell Mol Bioeng. 2012 Dec;5(4):502-413. doi: 10.1007/s12195-012-0253-8.\"\r\n",
      "\n",
      "ID =  \"Role of Epidermal Growth Factor-Triggered PI3K/Akt Signaling in the Migration of \n",
      "\n",
      "ID =  Medulloblastoma-Derived Cells.\"\r\n",
      "\n",
      "ID =  \"Dudu V(1), Able RA Jr, Rotari V, Kong Q, Vazquez M.\"\r\n",
      "\n",
      "ID =  \"Author information:\n",
      "\n",
      "ID =  (1)Department of Biomedical Engineering, The City College of the City University \n",
      "\n",
      "ID =  of New York (CCNY), 160 Convent Ave., Steinman Hall Room 403D, New York, NY \n",
      "\n",
      "ID =  10031, USA.\"\r\n",
      "\n",
      "ID =  \"Medulloblastoma (MB) is the most common brain cancer diagnosed among children. \n",
      "\n",
      "ID =  The cellular pathways that regulate MB invasion in response to environmental \n",
      "\n",
      "ID =  cues remain incompletely understood. Herein, we examine the migratory response \n",
      "\n",
      "ID =  of human MB-derived Daoy cells to different concentration profiles of Epidermal \n",
      "\n",
      "ID =  Growth Factor (EGF) using a microfluidic system. Our findings provide the first \n",
      "\n",
      "ID =  quantitative evidence that EGF concentration gradients modulate the chemotaxis \n",
      "\n",
      "ID =  of MB-derived cells in a dose-dependent manner via the EGF receptor (EGF-R). \n",
      "\n",
      "ID =  Data illustrates that higher concentration gradients caused increased number of \n",
      "\n",
      "ID =  cells to migrate. In addition, our results show that EGF-induced receptor \n",
      "\n",
      "ID =  phosphorylation triggered the downstream activation of phosphoinositide-3 kinase \n",
      "\n",
      "ID =  (PI3K)/Akt pathway, while its downstream activation was inhibited by Tarceva (an \n",
      "\n",
      "ID =  EGF-R inhibitor), and Wortmannin (a PI3K inhibitor). The treatment with \n",
      "\n",
      "ID =  inhibitors also severely reduced the number of MB-derived cells that migrated \n",
      "\n",
      "ID =  towards increasing EGF concentration gradients. Our results provide evidence to \n",
      "\n",
      "ID =  bolster the development of anti-migratory therapies as viable strategies to \n",
      "\n",
      "ID =  impede EGF-stimulated MB dispersal.\"\r\n",
      "\n",
      "ID =  \"DOI: 10.1007/s12195-012-0253-8\n",
      "\n",
      "ID =  PMCID: PMC3832994\n",
      "\n",
      "ID =  PMID: 24273611\"\r\n",
      "\n",
      "ID =  \"\n",
      "\n",
      "ID =  3. Memo. 2012 Sep;5(3):228-232. doi: 10.1007/s12254-012-0037-9. Epub 2012 Jul 20.\"\r\n",
      "\n",
      "ID =  Update on molecular and genetic alterations in adult medulloblastoma.\r\n",
      "\n",
      "ID =  \"Kool M(1), Korshunov A, Pfister SM.\"\r\n",
      "\n",
      "ID =  \"Author information:\n",
      "\n",
      "ID =  (1)Division of Pediatric Neurooncology, German Cancer Research Center DKFZ, Im \n",
      "\n",
      "ID =  Neuenheimer Feld 580, 69120 Heidelberg, Germany.\"\r\n",
      "\n",
      "ID =  \"Medulloblastoma encompasses a group of aggressively growing cancers that arise \n",
      "\n",
      "ID =  either in the cerebellum or brain stem. They present primarily in children, with \n",
      "\n",
      "ID =  80-85 % of medulloblastomas being diagnosed in patients of 16 years and younger. \n",
      "\n",
      "ID =  In adults, medulloblastomas are rare and account for less than 1 % of \n",
      "\n",
      "ID =  intracranial malignancies. Due to the low incidence of medulloblastoma in \n",
      "\n",
      "ID =  adults, the biology and genetics of adult medulloblastomas have long been poorly \n",
      "\n",
      "ID =  understood. Many centers therefore still treat adults either by radiotherapy \n",
      "\n",
      "ID =  only or by using glioblastoma protocols (both often noncurative), or with \n",
      "\n",
      "ID =  standard pediatric medulloblastoma regimes (often associated with dose-limiting \n",
      "\n",
      "ID =  toxicity).Current clinical staging systems discriminate between standard-risk or \n",
      "\n",
      "ID =  high-risk patients based on clinical and histological parameters. However, \n",
      "\n",
      "ID =  clinico-pathological features often fail to accurately predict treatment \n",
      "\n",
      "ID =  response. In children, molecularly defined risk assessment has become important \n",
      "\n",
      "ID =  to improve survival of high-risk patients and to decrease treatment-related \n",
      "\n",
      "ID =  toxicity and long-term sequelae in standard-risk patients. However, several \n",
      "\n",
      "ID =  recent studies have shown that adult and pediatric medulloblastomas are \n",
      "\n",
      "ID =  genetically distinct and may require different algorithms for molecular risk \n",
      "\n",
      "ID =  stratification. Moreover, four subtypes of medulloblastoma have been identified \n",
      "\n",
      "ID =  that appear at different frequencies in children and adults and that have a \n",
      "\n",
      "ID =  different prognostic impact depending on age. Molecular markers such as \n",
      "\n",
      "ID =  chromosome 10q and chromosome 17 statuses can be used for molecular risk \n",
      "\n",
      "ID =  stratification of adult medulloblastoma, but only in a subgroup-specific \n",
      "\n",
      "ID =  context. Here we present an overview of the current knowledge of the genomics of \n",
      "\n",
      "ID =  adult medulloblastoma and how these tumors differ from their pediatric \n",
      "\n",
      "ID =  counterparts.\"\r\n",
      "\n",
      "ID =  \"DOI: 10.1007/s12254-012-0037-9\n",
      "\n",
      "ID =  PMCID: PMC3458193\n",
      "\n",
      "ID =  PMID: 23864912\"\r\n",
      "\n",
      "ID =  \"\n",
      "\n",
      "ID =  4. Cancer Biol Med. 2012 Jun;9(2):137-40. doi: \n",
      "\n",
      "ID =  10.3969/j.issn.2095-3941.2012.02.011.\"\r\n",
      "\n",
      "ID =  Adult medulloblastoma associated with syringomyelia: a case report.\r\n",
      "\n",
      "ID =  Wang CC(1).\r\n",
      "\n",
      "ID =  \"Author information:\n",
      "\n",
      "ID =  (1)Nepean Hospital, Kingswood NSW 2747, Australia.\"\r\n",
      "\n",
      "ID =  \"The association between cerebellar medulloblastoma and syringomyelia is uncommon \n",
      "\n",
      "ID =  and only found in pediatric patients. To date, adult medulloblastoma associated \n",
      "\n",
      "ID =  with syringomyelia has not been reported in the literature. Paroxysmal \n",
      "\n",
      "ID =  bradycardia is an uncommon clinical manifestation in posterior fossa tumors and \n",
      "\n",
      "ID =  likely to be vagally mediated via brainstem preganglionic cardiac motor neurons. \n",
      "\n",
      "ID =  This report introduces the diagnosis and treatment of a case of adult \n",
      "\n",
      "ID =  medulloblastoma associated with syringomyelia, which presented with paroxysmal \n",
      "\n",
      "ID =  bradycardia.\"\r\n",
      "\n",
      "ID =  \"DOI: 10.3969/j.issn.2095-3941.2012.02.011\n",
      "\n",
      "ID =  PMCID: PMC3643653\n",
      "\n",
      "ID =  PMID: 23691470\"\r\n",
      "\n",
      "ID =  \"Conflict of interest statement: No potential conflicts of interest are \n",
      "\n",
      "ID =  disclosed.\"\r\n",
      "\n",
      "ID =  \"\n",
      "\n",
      "ID =  5. JIMD Rep. 2012;2:29-32. doi: 10.1007/8904_2011_39. Epub 2011 Sep 6.\"\r\n",
      "\n",
      "ID =  \"Onset of adreno-leukodystrophy after medulloblastoma therapy: causal connection \n",
      "\n",
      "ID =  or coincidence?\"\r\n",
      "\n",
      "ID =  \"Deib G(1), Poretti A, Meoded A, Cohen KJ, Raymond GV, Abromowitch M, Huisman TA.\"\r\n",
      "\n",
      "ID =  \"Author information:\n",
      "\n",
      "ID =  (1)Division of Neuroradiology, Russell H. Morgan Department of Radiology and \n",
      "\n",
      "ID =  Radiological Science, The Johns Hopkins University School of Medicine, \n",
      "\n",
      "ID =  Baltimore, MD, USA.\"\r\n",
      "\n",
      "ID =  \"X-linked adreno-leukodystrophy (ALD) is a peroxisomal disorder affecting the \n",
      "\n",
      "ID =  white matter of the central nervous system and the adrenal cortex. It is caused \n",
      "\n",
      "ID =  by mutations in the ABCD1 gene encoding for a peroxisomal membrane protein. The \n",
      "\n",
      "ID =  absent genotype-phenotype correlation implies a contribution by environmental \n",
      "\n",
      "ID =  factors to explain the phenotypical heterogeneity. We report on a 4-year-old boy \n",
      "\n",
      "ID =  with a biochemically confirmed diagnosis of ALD after birth. At the age of 32 \n",
      "\n",
      "ID =  months, the additional diagnosis of a medulloblastoma was made. After treatment \n",
      "\n",
      "ID =  of the medulloblastoma, he developed active areas of demyelination representing \n",
      "\n",
      "ID =  the characteristic neuroimaging features of ALD. The clinical history of our \n",
      "\n",
      "ID =  patient supports the hypothesis that external factors, like neurosurgical \n",
      "\n",
      "ID =  intervention as part of medulloblastoma treatment, may accelerate or initiate \n",
      "\n",
      "ID =  cerebral ALD-related demyelination. A postsurgical inflammatory reaction may \n",
      "\n",
      "ID =  facilitate the inclusion of abnormal fatty acids in myelin. The opening of the \n",
      "\n",
      "ID =  blood-brain barrier following neurosurgery may enhance the recognition of \n",
      "\n",
      "ID =  previously sequestered antigens considered to play a role in ALD onset. \n",
      "\n",
      "ID =  Consequently, neurosurgical disruption of the BBB can precipitate the \n",
      "\n",
      "ID =  immune-mediated inflammatory process, which progressively destroys myelin in ALD \n",
      "\n",
      "ID =  patients. Tumor-related chemotherapy and/or radiotherapy may also play a \n",
      "\n",
      "ID =  contributing role. We suggest that X-ALD patients who undergo neurosurgical \n",
      "\n",
      "ID =  intervention need close follow-up imaging to identify active demyelination \n",
      "\n",
      "ID =  early.\"\r\n",
      "\n",
      "ID =  \"DOI: 10.1007/8904_2011_39\n",
      "\n",
      "ID =  PMCID: PMC3509836\n",
      "\n",
      "ID =  PMID: 23430850\"\r\n",
      "\n",
      "ID =  \"\n",
      "\n",
      "ID =  6. Tumori. 2012 Nov;98(6):162e-4e. doi: 10.1700/1217.13513.\"\r\n",
      "\n",
      "ID =  Breast metastasis of anaplastic oligodendroglioma: a case report.\r\n",
      "\n",
      "ID =  \"Alacacioglu A(1), Unal S, Canpolat S, Yurt A, Oztekin O, Coskun A, Karatas A, \n",
      "\n",
      "ID =  Postaci H, Sop G.\"\r\n",
      "\n",
      "ID =  \"Author information:\n",
      "\n",
      "ID =  (1)Division of Medical Oncology, Department of Internal Medicine, Bozyaka \n",
      "\n",
      "ID =  Research and Training Hospital, Bozyaka, Izmir, Turkey. \n",
      "\n",
      "ID =  dralacacioglu@hotmail.com\"\r\n",
      "\n",
      "ID =  \"Extracranial metastasis of primary brain tumors is rarely observed. Of all brain \n",
      "\n",
      "ID =  malignancies, glioblastomas, medulloblastomas and astrocytomas metastasize most \n",
      "\n",
      "ID =  frequently. Metastasis of oligondendroglioma is rare. We present a case of \n",
      "\n",
      "ID =  breast metastasis in a 58-year-old man with an anaplastic oligodendroglioma.\"\r\n",
      "\n",
      "ID =  \"DOI: 10.1700/1217.13513\n",
      "\n",
      "ID =  PMID: 23389376 [Indexed for MEDLINE]\"\r\n",
      "\n",
      "ID =  \"\n",
      "\n",
      "ID =  7. Zh Vopr Neirokhir Im N N Burdenko. 2012;76(6):66-72.\"\r\n",
      "\n",
      "ID =  [Comparative assessment of molecular abberation in medulloblastomas].\r\n",
      "\n",
      "ID =  [Article in Russian]\r\n",
      "\n",
      "ID =  \"Ryzhova MV, Shishkina LV.\"\r\n",
      "\n",
      "ID =  \"Medulloblastoma is a heterogeneous disease with molecular variants and distinct \n",
      "\n",
      "ID =  biological behavior. Studying molecular abnormalities in medulloblastomas will \n",
      "\n",
      "ID =  allow to stratify patients into key populations and optimize aduvant therapy \n",
      "\n",
      "ID =  reducing long-term adverse effects.\"\r\n",
      "\n",
      "ID =  PMID: 23379186 [Indexed for MEDLINE]\r\n",
      "\n",
      "ID =  \"\n",
      "\n",
      "ID =  8. Front Neurosci. 2013 Jan 24;6:198. doi: 10.3389/fnins.2012.00198. eCollection \n",
      "\n",
      "ID =  2012.\"\r\n",
      "\n",
      "ID =  \"Medulloblastoma or not? Crucial role in tumorigenesis of the timing of migration \n",
      "\n",
      "ID =  of cerebellar granule precursor cells, regulated by Nos2 and Tis21.\"\r\n",
      "\n",
      "ID =  \"Farioli-Vecchioli S(1), Micheli L, Leonardi L, Ceccarelli M, Cavallaro S, Tirone \n",
      "\n",
      "ID =  F.\"\r\n",
      "\n",
      "ID =  \"Author information:\n",
      "\n",
      "ID =  (1)Institute of Cell Biology and Neurobiology, National Research Council, \n",
      "\n",
      "ID =  Fondazione Santa Lucia Rome, Italy.\"\r\n",
      "\n",
      "ID =  \"DOI: 10.3389/fnins.2012.00198\n",
      "\n",
      "ID =  PMCID: PMC3553397\n",
      "\n",
      "ID =  PMID: 23355800\"\r\n",
      "\n",
      "ID =  \"\n",
      "\n",
      "ID =  9. Rev Med Chil. 2012 Sep;140(9):1116-25. doi: 10.4067/S0034-98872012000900003.\"\r\n",
      "\n",
      "ID =  \"[Positron emission tomography with fluorine-deoxyglucose in sarcomas and \n",
      "\n",
      "ID =  non-sarcoma non-epithelial tumors].\"\r\n",
      "\n",
      "ID =  [Article in Spanish]\r\n",
      "\n",
      "ID =  \"Massardo T(1), Jofré MJ, Sierralta MP, Canessa J, Castro G, Berrocal I, Gallegos \n",
      "\n",
      "ID =  I.\"\r\n",
      "\n",
      "ID =  \"Author information:\n",
      "\n",
      "ID =  (1)Sección Medicina Nuclear, Departamento de Medicina, Hospital Clínico \n",
      "\n",
      "ID =  Universidad de Chile, Chile. tmassardo@redclinicauchile.cl\"\r\n",
      "\n",
      "ID =  \"BACKGROUND: The usefulness of positron emission tomography (PET) with \n",
      "\n",
      "ID =  fluorine-deoxyglucose (FDG) in sarcomas and non-sarcoma non-epithelial (NSNE) \n",
      "\n",
      "ID =  tumors is not clearly defined.\n",
      "\n",
      "ID =  AIM: To report a Chilean experience with NSNE tumors evaluated using PET with \n",
      "\n",
      "ID =  FDG.\n",
      "\n",
      "ID =  MATERIAL AND METHODS: Retrospective review of the database of a PET laboratory. \n",
      "\n",
      "ID =  Demographic data, indications and metabolic findings were compared with \n",
      "\n",
      "ID =  conventional imaging in 88 adults and children with diverse bone and soft tissue \n",
      "\n",
      "ID =  sarcomas as well as 24 gastrointestinal stromal tumors (GIST), 6 pleural \n",
      "\n",
      "ID =  malignant mesotheliomas in adults, and 9 medulloblastomas in children.\n",
      "\n",
      "ID =  RESULTS: FDG showed good concordance with conventional imaging in NSNE tumors. \n",
      "\n",
      "ID =  It was helpful for staging, restaging, follow-up after treatment and for the \n",
      "\n",
      "ID =  detection of new not previously suspected lesions.\n",
      "\n",
      "ID =  CONCLUSIONS: PET with FDG could have a prognostic role and help in patient \n",
      "\n",
      "ID =  management, mainly in musculoskeletal and high grade or less differentiated \n",
      "\n",
      "ID =  sarcomas. In GIST, it was a good tool for immunotherapy control.\"\r\n",
      "\n",
      "ID =  \"DOI: 10.4067/S0034-98872012000900003\n",
      "\n",
      "ID =  PMID: 23354632 [Indexed for MEDLINE]\"\r\n",
      "\n",
      "ID =  \"\n",
      "\n",
      "ID =  10. Oncology (Williston Park). 2012 Nov;26(11):1097, 1102.\"\r\n",
      "\n",
      "ID =  Medulloblastoma: molecular classifications and prognostic associations.\r\n",
      "\n",
      "ID =  \"Shrieve DC(1), Colman H.\"\r\n",
      "\n",
      "ID =  \"Author information:\n",
      "\n",
      "ID =  (1)Department of Radiation Oncology, The Huntsman Cancer Hospital, USA.\"\r\n",
      "\n",
      "ID =  \"Comment on\n",
      "\n",
      "ID =      Oncology (Williston Park). 2012 Nov;26(11):1083-91.\"\r\n",
      "\n",
      "ID =  PMID: 23330355 [Indexed for MEDLINE]\r\n",
      "\n",
      "ID =  \"\n",
      "\n",
      "ID =  11. Oncology (Williston Park). 2012 Nov;26(11):1095-7.\"\r\n",
      "\n",
      "ID =  A tale of two tumors: pediatric and adult medulloblastoma.\r\n",
      "\n",
      "ID =  \"Aizer AA(1), Chan AW.\"\r\n",
      "\n",
      "ID =  \"Author information:\n",
      "\n",
      "ID =  (1)Dept of Radiation Oncology, Massachusetts General Hospital (MGH), Harvard \n",
      "\n",
      "ID =  Medical School, Boston, Massachusetts, USA.\"\r\n",
      "\n",
      "ID =  \"Comment on\n",
      "\n",
      "ID =      Oncology (Williston Park). 2012 Nov;26(11):1083-91.\"\r\n",
      "\n",
      "ID =  PMID: 23330354 [Indexed for MEDLINE]\r\n",
      "\n",
      "ID =  \"\n",
      "\n",
      "ID =  12. Oncology (Williston Park). 2012 Nov;26(11):1083-91.\"\r\n",
      "\n",
      "ID =  \"Adult medulloblastoma, from spongioblastoma cerebelli to the present day: a \n",
      "\n",
      "ID =  review of treatment and the integration of molecular markers.\"\r\n",
      "\n",
      "ID =  \"Shonka N(1), Brandes A, De Groot JF.\"\r\n",
      "\n",
      "ID =  \"Author information:\n",
      "\n",
      "ID =  (1)Division of Oncology and Hematology, University of Nebraska Medical Center, \n",
      "\n",
      "ID =  Omaha, Nebraska 68198-7680, USA. nshonka@unmc.edu\"\r\n",
      "\n",
      "ID =  \"Comment in\n",
      "\n",
      "ID =      Oncology (Williston Park). 2012 Nov;26(11):1095-7.\n",
      "\n",
      "ID =      Oncology (Williston Park). 2012 Nov;26(11):1097, 1102.\"\r\n",
      "\n",
      "ID =  \"Although they represent the most common malignant brain tumor in the pediatric \n",
      "\n",
      "ID =  population, medulloblastomas are rare in adults, with an incidence of 0.5 per \n",
      "\n",
      "ID =  million. With only one exception, all of the prospective clinical trials in this \n",
      "\n",
      "ID =  disease have been done in the pediatric population, and therefore therapy for \n",
      "\n",
      "ID =  adult medulloblastoma has been either extrapolated from the pediatric literature \n",
      "\n",
      "ID =  or based on retrospective reviews. A growing body of literature underscores the \n",
      "\n",
      "ID =  genetic similarities between adult and pediatric disease, which may allow \n",
      "\n",
      "ID =  tailored therapy directed towards specific molecular pathways and may have an \n",
      "\n",
      "ID =  impact on clinical outcomes. Here we present the history, staging system, and \n",
      "\n",
      "ID =  treatment of medulloblastoma, reviewing the prognostic value and clinical \n",
      "\n",
      "ID =  application of molecular subtyping while highlighting the differences between \n",
      "\n",
      "ID =  adult and pediatric disease.\"\r\n",
      "\n",
      "ID =  PMID: 23330353 [Indexed for MEDLINE]\r\n",
      "\n",
      "ID =  \"\n",
      "\n",
      "ID =  13. Zhonghua Bing Li Xue Za Zhi. 2012 Dec;41(12):823-7. doi: \n",
      "\n",
      "ID =  10.3760/cma.j.issn.0529-5807.2012.12.007.\"\r\n",
      "\n",
      "ID =  \"[Clinicopathologic significance of β-catenin protein and loss of heterozygosity \n",
      "\n",
      "ID =  on 10q in medulloblastoma].\"\r\n",
      "\n",
      "ID =  [Article in Chinese]\r\n",
      "\n",
      "ID =  \"Li JZ(1), Wang CH, Zhou FA, Miao N, Abulajang G, Zhang W.\"\r\n",
      "\n",
      "ID =  \"Author information:\n",
      "\n",
      "ID =  (1)Department of Pathology, the First Affiliated Hospital of Xinjiang Medical \n",
      "\n",
      "ID =  University, Urumqi 830054, China.\"\r\n",
      "\n",
      "ID =  \"OBJECTIVE: To study the expression of β-catenin protein and the status of loss \n",
      "\n",
      "ID =  of heterozygosity (LOH) on chromsome 10q in medulloblastoma, with clinical \n",
      "\n",
      "ID =  correlation.\n",
      "\n",
      "ID =  METHODS: Immunohistochemical study for β-catenin protein was carried out in 50 \n",
      "\n",
      "ID =  cases of medulloblastoma encountered in the First Affiliated Hospital of \n",
      "\n",
      "ID =  Xinjiang Medical University during the period from 2002 to 2011, including 32 \n",
      "\n",
      "ID =  cases of classic medulloblastoma, 13 cases of desmoplastic medulloblastoma and 5 \n",
      "\n",
      "ID =  cases of medulloblastoma with extensive nodularity. The status of LOH on 10q was \n",
      "\n",
      "ID =  also detected by fluorescence in-situ hybridization. The clinicopathologic \n",
      "\n",
      "ID =  characteristics and prognostic parameters were studied by Kaplan-Meien and Cox \n",
      "\n",
      "ID =  analysis.\n",
      "\n",
      "ID =  RESULTS: The rates of expression of β-catenin protein in classic \n",
      "\n",
      "ID =  medulloblastoma, desmoplastic medulloblastoma and medulloblastoma with extensive \n",
      "\n",
      "ID =  nodularity were 53.1% (17/32), 4/13 and 1/5, respectively. The rate of LOH on \n",
      "\n",
      "ID =  10q was 33.3% (8/24) in classic medulloblastoma and 2/11 in desmoplastic \n",
      "\n",
      "ID =  medulloblastoma. There was no statistically significant difference between the \n",
      "\n",
      "ID =  two tumor types. Univariate analysis showed that the expression of β-catenin \n",
      "\n",
      "ID =  protein (P = 0.022), lack of LOH on 10q (P = 0.020), extensiveness of tumor \n",
      "\n",
      "ID =  resection (P < 0.01), radiotherapy (P = 0.002) and chemotherapy (P < 0.01) \n",
      "\n",
      "ID =  represented important prognostic factors.\n",
      "\n",
      "ID =  CONCLUSIONS: Medulloblastoma with expression of β-catenin protein and without \n",
      "\n",
      "ID =  LOH on 10q carries a better prognosis. Assessment of these parameters is helpful \n",
      "\n",
      "ID =  in evaluating prognosis and subsequent patient management.\"\r\n",
      "\n",
      "ID =  \"DOI: 10.3760/cma.j.issn.0529-5807.2012.12.007\n",
      "\n",
      "ID =  PMID: 23324231 [Indexed for MEDLINE]\"\r\n",
      "\n",
      "ID =  \"\n",
      "\n",
      "ID =  14. Transl Oncol. 2012 Dec;5(6):408-14. doi: 10.1593/tlo.12277. Epub 2012 Dec 1.\"\r\n",
      "\n",
      "ID =  \"Microscopic Delineation of Medulloblastoma Margins in a Transgenic Mouse Model \n",
      "\n",
      "ID =  Using a Topically Applied VEGFR-1 Probe.\"\r\n",
      "\n",
      "ID =  \"Wang D(1), Chen Y, Leigh SY, Haeberle H, Contag CH, Liu JT.\"\r\n",
      "\n",
      "ID =  \"Author information:\n",
      "\n",
      "ID =  (1)Department of Biomedical Engineering, State University of New York (SUNY) at \n",
      "\n",
      "ID =  Stony Brook, Stony Brook, NY.\"\r\n",
      "\n",
      "ID =  \"The unambiguous demarcation of tumor margins is critical at the final stages in \n",
      "\n",
      "ID =  the surgical treatment of brain tumors because patient outcomes have been shown \n",
      "\n",
      "ID =  to correlate with the extent of resection. Real-time high-resolution imaging \n",
      "\n",
      "ID =  with the aid of a tumor-targeting fluorescent contrast agent has the potential \n",
      "\n",
      "ID =  to enable intraoperative differentiation of tumor versus normal tissues with \n",
      "\n",
      "ID =  accuracy approaching the current gold standard of histopathology. In this study, \n",
      "\n",
      "ID =  a monoclonal antibody targeting the vascular endothelial growth factor receptor \n",
      "\n",
      "ID =  1 (VEGFR-1) was conjugated to fluorophores and evaluated as a tumor contrast \n",
      "\n",
      "ID =  agent in a transgenic mouse model of medulloblastoma. The probe was administered \n",
      "\n",
      "ID =  topically, and its efficacy as an imaging agent was evaluated in vitro using \n",
      "\n",
      "ID =  flow cytometry, as well as ex vivo on fixed and fresh tissues through \n",
      "\n",
      "ID =  immunohistochemistry and dual-axis confocal microscopy, respectively. Results \n",
      "\n",
      "ID =  show a preferential binding to tumor versus normal tissue, suggesting that a \n",
      "\n",
      "ID =  topically applied VEGFR-1 probe can potentially be used with real-time \n",
      "\n",
      "ID =  intraoperative optical sectioning microscopy to guide brain tumor resections.\"\r\n",
      "\n",
      "ID =  \"DOI: 10.1593/tlo.12277\n",
      "\n",
      "ID =  PMCID: PMC3542836\n",
      "\n",
      "ID =  PMID: 23323155\"\r\n",
      "\n",
      "ID =  \"\n",
      "\n",
      "ID =  15. Folia Neuropathol. 2012;50(4):375-81. doi: 10.5114/fn.2012.32367.\"\r\n",
      "\n",
      "ID =  \"Toll-like receptors as an innate immunity bridge to neuroinflammation in \n",
      "\n",
      "ID =  medulloblastoma.\"\r\n",
      "\n",
      "ID =  \"Maslinska D(1), Laure-Kamionowska M, Maślinska S.\"\r\n",
      "\n",
      "ID =  \"Author information:\n",
      "\n",
      "ID =  (1)Department of Experimental and Clinical Neuropathology, Mossakowski Medical \n",
      "\n",
      "ID =  Research Centre, Polish Academy of Sciences, Warsaw, Poland. \n",
      "\n",
      "ID =  maslinskad@imdik.pan.pl\"\r\n",
      "\n",
      "ID =  \"The relationship between inflammation, immunity and cancer is widely accepted \n",
      "\n",
      "ID =  but mechanisms mediating this relationship remain unknown. Our present study was \n",
      "\n",
      "ID =  undertaken to examine the presence and distribution of Toll-like receptors \n",
      "\n",
      "ID =  (TLRs) in necrotic areas of medulloblastoma. These receptors fulfil the criteria \n",
      "\n",
      "ID =  postulated for the receptors of innate immunity and signalling from TLRs induces \n",
      "\n",
      "ID =  synthesis of various pro-inflammatory cytokines, enzymes and mediators. The \n",
      "\n",
      "ID =  study was performed on human medulloblastoma samples containing areas of \n",
      "\n",
      "ID =  necrosis within the tumour and/or within the normal nerve tissue at the \n",
      "\n",
      "ID =  periphery of the tumour. Proteins of four TLRs: TLR 2, 3, 4 and 9 were detected \n",
      "\n",
      "ID =  in the tissue with the immunohistochemical method using the specific antibodies. \n",
      "\n",
      "ID =  Two types of necrotic areas were found. In the first type, the area of dead \n",
      "\n",
      "ID =  cells was surrounded by undifferentiated medulloblastoma cells. A lot of these \n",
      "\n",
      "ID =  cells expressed TLR 2 and TLR 3 antigens. TLR 2 was also expressed on the wall \n",
      "\n",
      "ID =  of de novo formed blood vessels that fill tumour regions already cleared from \n",
      "\n",
      "ID =  dead cells. The second type of necrotic areas were found at the periphery of the \n",
      "\n",
      "ID =  tumour and composed of normal nerve tissue cells. TLR 2, TLR 3 and TLR 9 were \n",
      "\n",
      "ID =  detected in hypertrophic glia cells. Our findings show a new function of TLRs as \n",
      "\n",
      "ID =  sensors of pathogens released by medulloblastoma dead cells. This new function \n",
      "\n",
      "ID =  may provide a key link connecting innate immunity, neuroinflammation and \n",
      "\n",
      "ID =  angiogenesis in the tumour.\"\r\n",
      "\n",
      "ID =  \"DOI: 10.5114/fn.2012.32367\n",
      "\n",
      "ID =  PMID: 23319193 [Indexed for MEDLINE]\"\r\n",
      "\n",
      "ID =  \"\n",
      "\n",
      "ID =  16. Front Oncol. 2012 Dec 11;2:185. doi: 10.3389/fonc.2012.00185. eCollection\n",
      "\n",
      "ID =  2012.\"\r\n",
      "\n",
      "ID =  \"Radiation therapy quality in CCG/POG intergroup 9961: implications for \n",
      "\n",
      "ID =  craniospinal irradiation and the posterior fossa boost in future medulloblastoma \n",
      "\n",
      "ID =  trials.\"\r\n",
      "\n",
      "ID =  \"Donahue B(1), Marymont MA, Kessel S, Iandoli MK, Fitzgerald T, Holmes E, Kocak \n",
      "\n",
      "ID =  M, Boyett JM, Gajjar A, Packer RJ.\"\r\n",
      "\n",
      "ID =  \"Author information:\n",
      "\n",
      "ID =  (1)New York University School of Medicine New York, NY, USA.\"\r\n",
      "\n",
      "ID =  \"PURPOSE: Associations of radiation therapy (RT) deviations and outcomes in \n",
      "\n",
      "ID =  medulloblastoma have not been defined well, particularly in the era of \n",
      "\n",
      "ID =  reduced-dose craniospinal irradiation and chemotherapy. The aim of this study is \n",
      "\n",
      "ID =  to evaluate the quality of RT on Children's Cancer Group/Pediatric Oncology \n",
      "\n",
      "ID =  Group 9961 and analyze associations of RT deviations with outcome.\n",
      "\n",
      "ID =  MATERIALS AND METHODS: Major volume deviations were assessed based on the \n",
      "\n",
      "ID =  distance from specified anatomical region to field edge. We investigated \n",
      "\n",
      "ID =  associations of RT deviations with progression-free survival (PFS), overall \n",
      "\n",
      "ID =  survival (OS), and explored associations with demographics and clinical \n",
      "\n",
      "ID =  variables.\n",
      "\n",
      "ID =  RESULTS: Of the 308 patients who were evaluable for volume deviations, 101 \n",
      "\n",
      "ID =  patients (33%) did not have any. Of the remaining 207 patients, 50% had only \n",
      "\n",
      "ID =  minor deviations, 29% had only major deviations, and 21% had both minor and \n",
      "\n",
      "ID =  major deviations. Of the patients with major deviations, 73% had a single major \n",
      "\n",
      "ID =  deviation. The most common major deviation was in the cribriform plate region, \n",
      "\n",
      "ID =  followed by the posterior fossa (PF); PF deviations resulted from treating less \n",
      "\n",
      "ID =  than whole PF. There were no significant differences in PFS or OS between \n",
      "\n",
      "ID =  patients with deviations and those without. There was no evidence of \n",
      "\n",
      "ID =  associations of deviations with patient age.\n",
      "\n",
      "ID =  CONCLUSIONS: Approximately one-third of patients had major volume deviations. \n",
      "\n",
      "ID =  There was no evidence of a significant association between these and outcome. \n",
      "\n",
      "ID =  This lack of correlation likely reflects the current high quality of RT \n",
      "\n",
      "ID =  delivered in Children's Oncology Group institutions, our strict definition of \n",
      "\n",
      "ID =  volume deviations, and the relatively few instances of multiple major deviations \n",
      "\n",
      "ID =  in individual patients. In is noteworthy that the types of PF volume deviations \n",
      "\n",
      "ID =  observed in this study were not adversely associated with outcome. As we move \n",
      "\n",
      "ID =  forward, quality assurance will continue to play an important role to ensure \n",
      "\n",
      "ID =  that deviations on study do not influence study outcome.\"\r\n",
      "\n",
      "ID =  \"DOI: 10.3389/fonc.2012.00185\n",
      "\n",
      "ID =  PMCID: PMC3540930\n",
      "\n",
      "ID =  PMID: 23316474\"\r\n",
      "\n",
      "ID =  \"\n",
      "\n",
      "ID =  17. Med Image Comput Comput Assist Interv. 2012;15(Pt 1):157-64. doi: \n",
      "\n",
      "ID =  10.1007/978-3-642-33415-3_20.\"\r\n",
      "\n",
      "ID =  \"A visual latent semantic approach for automatic analysis and interpretation of \n",
      "\n",
      "ID =  anaplastic medulloblastoma virtual slides.\"\r\n",
      "\n",
      "ID =  \"Cruz-Roa A(1), González F, Galaro J, Judkins AR, Ellison D, Baccon J, Madabhushi \n",
      "\n",
      "ID =  A, Romero E.\"\r\n",
      "\n",
      "ID =  \"Author information:\n",
      "\n",
      "ID =  (1)BioIngenium Research Group, Universidad Nacional de Colombia, Bogota, \n",
      "\n",
      "ID =  Colombia.\"\r\n",
      "\n",
      "ID =  \"A method for automatic analysis and interpretation of histopathology images is \n",
      "\n",
      "ID =  presented. The method uses a representation of the image data set based on bag \n",
      "\n",
      "ID =  of features histograms built from visual dictionary of Haar-based patches and a \n",
      "\n",
      "ID =  novel visual latent semantic strategy for characterizing the visual content of a \n",
      "\n",
      "ID =  set of images. One important contribution of the method is the provision of an \n",
      "\n",
      "ID =  interpretability layer, which is able to explain a particular classification by \n",
      "\n",
      "ID =  visually mapping the most important visual patterns associated with such \n",
      "\n",
      "ID =  classification. The method was evaluated on a challenging problem involving \n",
      "\n",
      "ID =  automated discrimination of medulloblastoma tumors based on image derived \n",
      "\n",
      "ID =  attributes from whole slide images as anaplastic or non-anaplastic. The data set \n",
      "\n",
      "ID =  comprised 10 labeled histopathological patient studies, 5 for anaplastic and 5 \n",
      "\n",
      "ID =  for non-anaplastic, where 750 square images cropped randomly from cancerous \n",
      "\n",
      "ID =  region from whole slide per study. The experimental results show that the new \n",
      "\n",
      "ID =  method is competitive in terms of classification accuracy achieving 0.87 in \n",
      "\n",
      "ID =  average.\"\r\n",
      "\n",
      "ID =  \"DOI: 10.1007/978-3-642-33415-3_20\n",
      "\n",
      "ID =  PMID: 23285547 [Indexed for MEDLINE]\"\r\n",
      "\n",
      "ID =  \"\n",
      "\n",
      "ID =  18. Pediatr Blood Cancer. 2013 Apr;60(4):642-9. doi: 10.1002/pbc.24409. Epub 2012\n",
      "\n",
      "ID =   Dec 31.\"\r\n",
      "\n",
      "ID =  \"Malnutrition in pediatric patients with cancer at diagnosis and throughout \n",
      "\n",
      "ID =  therapy: A multicenter cohort study.\"\r\n",
      "\n",
      "ID =  \"Zimmermann K(1), Ammann RA, Kuehni CE, De Geest S, Cignacco E.\"\r\n",
      "\n",
      "ID =  \"Author information:\n",
      "\n",
      "ID =  (1)Institute of Nursing Science, University of Basel, Basel, Switzerland.\"\r\n",
      "\n",
      "ID =  \"BACKGROUND: Malnutrition is a common problem in pediatric patients with cancer. \n",
      "\n",
      "ID =  Reported prevalence varies widely and has often been assessed only in a subset \n",
      "\n",
      "ID =  of childhood types of cancer. This study aimed to describe the prevalence of \n",
      "\n",
      "ID =  malnutrition among pediatric patients newly diagnosed with cancer, to describe \n",
      "\n",
      "ID =  the occurrence and course of malnutrition during therapy and to identify factors \n",
      "\n",
      "ID =  associated with malnutrition during therapy.\n",
      "\n",
      "ID =  PROCEDURE: In a retrospective cohort study of 327 patients diagnosed from 2003 \n",
      "\n",
      "ID =  to 2006 in three Swiss tertiary care hospitals, weight and height measures \n",
      "\n",
      "ID =  together with patient-, disease-, and treatment-related characteristics were \n",
      "\n",
      "ID =  assessed. Malnutrition was defined as body mass index (BMI) below -2 standard \n",
      "\n",
      "ID =  deviation scores (SDS) or a weight loss >10% from diagnosis. Malnutrition was \n",
      "\n",
      "ID =  assessed at diagnosis and continuously during anticancer therapy.\n",
      "\n",
      "ID =  RESULTS: At diagnosis, 5.8% of the patients (19) were malnourished based on BMI. \n",
      "\n",
      "ID =  During anticancer therapy, the cumulative incidence of malnutrition rose to 22% \n",
      "\n",
      "ID =  (70 patients) after 30 days, to 36% (116 patients) after 60 days, and finally to \n",
      "\n",
      "ID =  47% (155 patients). In these 155 patients, the median duration of malnutrition \n",
      "\n",
      "ID =  was 60 days (interquartile range, 21-122). Age above 10 years at diagnosis, BMI \n",
      "\n",
      "ID =  ≤ -1.0 SDS at diagnosis, and a diagnosis of medulloblastoma were positively \n",
      "\n",
      "ID =  associated with a higher proportion of malnutrition time during therapy.\n",
      "\n",
      "ID =  CONCLUSIONS: The rapid increase of malnutrition after the start of treatment \n",
      "\n",
      "ID =  underlines the need to develop evidence-based and efficient methods to provide \n",
      "\n",
      "ID =  nutritional support for children with cancer.\"\r\n",
      "\n",
      "ID =  \"Copyright © 2012 Wiley Periodicals, Inc.\"\r\n",
      "\n",
      "ID =  \"DOI: 10.1002/pbc.24409\n",
      "\n",
      "ID =  PMID: 23281136 [Indexed for MEDLINE]\"\r\n",
      "\n",
      "ID =  \"\n",
      "\n",
      "ID =  19. Eur J Paediatr Neurol. 2013 May;17(3):302-7. doi: 10.1016/j.ejpn.2012.12.002.\n",
      "\n",
      "ID =   Epub 2012 Dec 27.\"\r\n",
      "\n",
      "ID =  \"Differentiation between high and low grade tumours in paediatric patients by \n",
      "\n",
      "ID =  using apparent diffusion coefficients.\"\r\n",
      "\n",
      "ID =  \"Porto L(1), Jurcoane A, Schwabe D, Kieslich M, Hattingen E.\"\r\n",
      "\n",
      "ID =  \"Author information:\n",
      "\n",
      "ID =  (1)Neuroradiology Department of the Johann Wolfgang Goethe University, \n",
      "\n",
      "ID =  Frankfurt/Main, Germany. luciana.porto@kgu.de\"\r\n",
      "\n",
      "ID =  \"OBJECTIVE: This study was performed to confirm the hypothesis that pre-operative \n",
      "\n",
      "ID =  apparent diffusion coefficient (ADC) can be used to distinguish between \"\"low \n",
      "\n",
      "ID =  grade\"\" and \"\"high grade\"\" tumours in paediatric patients.\n",
      "\n",
      "ID =  MATERIAL AND METHODS: ADC values were retrospectively evaluated in thirty-six \n",
      "\n",
      "ID =  paediatric brain tumours. Twenty-one children with low grade brain tumours (12 \n",
      "\n",
      "ID =  WHO I astrocytomas, 1 giant cell tumour, 1 pilomyxoid astrocytoma, 4 WHO II \n",
      "\n",
      "ID =  astrocytomas, 2 craniopharyngiomas and 1 ganglioglioma) and 15 children with \n",
      "\n",
      "ID =  high grade brain tumours (6 medulloblastomas, 3 WHO III ependymomas, 1 PNET, 1 \n",
      "\n",
      "ID =  malignant rhabdoid tumour, 1 malignant germ cell tumour, 1 WHO III astrocytoma, \n",
      "\n",
      "ID =  1 WHO IV astrocytoma, 1 rhabdomyosarcoma metastasis) were included in this \n",
      "\n",
      "ID =  study. Minimum and mean ADC values were compared between low grade and high \n",
      "\n",
      "ID =  grade tumours and cut-off values were evaluated.\n",
      "\n",
      "ID =  RESULTS: The cut-off values to differentiate low and high grade paediatric brain \n",
      "\n",
      "ID =  tumours were 0.7 × 10(-3) mm(2)/s and 1.0 × 10(-3) mm(2)/s for minimum ADC and \n",
      "\n",
      "ID =  average ADC values respectively. All but one high grade infratentorial \n",
      "\n",
      "ID =  ependymoma showed significantly lower ADC values than low grade brain tumours in \n",
      "\n",
      "ID =  children.\n",
      "\n",
      "ID =  CONCLUSION: Combining the information obtained from conventional MR imaging with \n",
      "\n",
      "ID =  the ADC values may increase the accuracy of pre-operative differentiation \n",
      "\n",
      "ID =  between low grade and high grade paediatric tumours. Cut-off values can help to \n",
      "\n",
      "ID =  discern low from high grade tumours. However, it has to be considered that there \n",
      "\n",
      "ID =  is a substantial overlap between tumour types previously described in the \n",
      "\n",
      "ID =  literature.\"\r\n",
      "\n",
      "ID =  \"Copyright © 2012 European Paediatric Neurology Society. Published by Elsevier \n",
      "\n",
      "ID =  Ltd. All rights reserved.\"\r\n",
      "\n",
      "ID =  \"DOI: 10.1016/j.ejpn.2012.12.002\n",
      "\n",
      "ID =  PMID: 23273960 [Indexed for MEDLINE]\"\r\n",
      "\n",
      "ID =  \"\n",
      "\n",
      "ID =  20. Pediatr Hematol Oncol. 2013 Feb;30(1):28-9. doi:\n",
      "\n",
      "ID =  10.3109/08880018.2012.748856.  Epub 2012 Dec 28.\"\r\n",
      "\n",
      "ID =  \"Chronic myeloid leukemia as a second malignant neoplasm in a patient with \n",
      "\n",
      "ID =  medulloblastoma after treatment with chemotherapy and irradiation: a case report \n",
      "\n",
      "ID =  and review of the literature.\"\r\n",
      "\n",
      "ID =  \"Dhir N(1), Zaky W, Zomorodian T, Dhall G.\"\r\n",
      "\n",
      "ID =  \"Author information:\n",
      "\n",
      "ID =  (1)Neuro-oncology Program, Children's Hospital Los Angeles, Los Angeles, \n",
      "\n",
      "ID =  California, USA.\"\r\n",
      "\n",
      "ID =  \"DOI: 10.3109/08880018.2012.748856\n",
      "\n",
      "ID =  PMID: 23273112 [Indexed for MEDLINE]\"\r\n",
      "\n"
     ]
    }
   ],
   "source": [
    "cur = cursor.execute(\"SELECT abstract from abstracts\")\n",
    "for row in cur:\n",
    "   print \"ID = \", row[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "72782f45",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Commit the changes and close the database connection\n",
    "conn.commit()\n",
    "conn.close()"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 2",
   "language": "python",
   "name": "python2"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 2
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython2",
   "version": "2.7.18"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
